177 related articles for article (PubMed ID: 23039402)
1. Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Plant D; Ibrahim I; Lunt M; Eyre S; Flynn E; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
Arthritis Res Ther; 2012 Oct; 14(5):R214. PubMed ID: 23039402
[TBL] [Abstract][Full Text] [Related]
2. Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Bluett J; Ibrahim I; Plant D; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
Pharmacogenomics J; 2014 Apr; 14(2):171-5. PubMed ID: 23856853
[TBL] [Abstract][Full Text] [Related]
3. CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients.
Ammitzbøll CG; Steffensen R; Bøgsted M; Hørslev-Petersen K; Hetland ML; Junker P; Johansen JS; Pødenphant J; Østergaard M; Ellingsen T; Stengaard-Pedersen K
Arthritis Res Ther; 2014 Oct; 16(5):475. PubMed ID: 25359432
[TBL] [Abstract][Full Text] [Related]
4. DAS28-ESR and DAS28-CRP - are they Interchangeable in Measuring the Activity of Rheumatoid Arthritis in Response to Treatment with Biological Agents?
Shivacheva TK
Folia Med (Plovdiv); 2020 Mar; 62(1):46-51. PubMed ID: 32337896
[TBL] [Abstract][Full Text] [Related]
5. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
6. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
7. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response.
Viatte S; Plant D; Han B; Fu B; Yarwood A; Thomson W; Symmons DP; Worthington J; Young A; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; Raychaudhuri S; Barton A
JAMA; 2015 Apr; 313(16):1645-56. PubMed ID: 25919528
[TBL] [Abstract][Full Text] [Related]
8. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
9. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.
Hassan B; Maxwell JR; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
Rheumatology (Oxford); 2010 Jan; 49(1):43-7. PubMed ID: 19926672
[TBL] [Abstract][Full Text] [Related]
10. Effect of Sanhuangyilong decoction plus methotrexate on tumor necrosis factor alpha and interferon gamma in serum and synovial fluid in rheumatoid arthritis patients with symptom pattern of damp heat obstruction.
Liu D; Yan J; Yun M; Yang M; Luo Y; Zhang J; Guo M; Yang M; Yuan W; Zou W; Li H; Hu Y
J Tradit Chin Med; 2016 Oct; 36(5):625-33. PubMed ID: 29933531
[TBL] [Abstract][Full Text] [Related]
11. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.
Mathews RJ; Robinson JI; Battellino M; Wong C; Taylor JC; ; Eyre S; Churchman SM; Wilson AG; Isaacs JD; Hyrich K; Barton A; Plant D; Savic S; Cook GP; Sarzi-Puttini P; Emery P; Barrett JH; Morgan AW; McDermott MF
Ann Rheum Dis; 2014 Jun; 73(6):1202-10. PubMed ID: 23687262
[TBL] [Abstract][Full Text] [Related]
12. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Bluett J; Morgan C; Thurston L; Plant D; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; Cordingley L; Barton A;
Rheumatology (Oxford); 2015 Mar; 54(3):494-9. PubMed ID: 25213131
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
[TBL] [Abstract][Full Text] [Related]
14. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
[TBL] [Abstract][Full Text] [Related]
15. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
[TBL] [Abstract][Full Text] [Related]
16. A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.
Rhodes B; Merriman ME; Harrison A; Nissen MJ; Smith M; Stamp L; Steer S; Merriman TR; Vyse TJ
PLoS Med; 2010 Sep; 7(9):e1000341. PubMed ID: 20877716
[TBL] [Abstract][Full Text] [Related]
17. Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study.
Johnson J; Yeter K; Rajbhandary R; Neal R; Tian Q; Jian J; Fadle N; Thurner L; Liu C; Stohl W
Clin Rheumatol; 2017 Mar; 36(3):507-516. PubMed ID: 27830341
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis.
Sengul I; Akcay-Yalbuzdag S; Ince B; Goksel-Karatepe A; Kaya T
Int J Rheum Dis; 2015 Jul; 18(6):640-5. PubMed ID: 26013310
[TBL] [Abstract][Full Text] [Related]
19. Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.
Kuriya B; Schieir O; Lin D; Xiong J; Pope J; Boire G; Haraoui B; Thorne JC; Tin D; Hitchon C; Jamal S; Keystone E; Bykerk VP;
Clin Exp Rheumatol; 2017; 35(5):799-803. PubMed ID: 28339365
[TBL] [Abstract][Full Text] [Related]
20. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
